Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency
Deficient antibody production in patients with common variable immunodeficiency (CVID) is accompanied by an inability to produce free light chains (FLCs), particularly kappa (κ) FLC, due to B-cell dysfunction. We found that intravenous immunoglobulin (IVIg) administration, in a patient with CVID and...
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Taylor & Francis Group
2019-05-01
|
| Sarja: | Human Vaccines & Immunotherapeutics |
| Aiheet: | |
| Linkit: | http://dx.doi.org/10.1080/21645515.2019.1572411 |